论文部分内容阅读
鉴于桂林集琦药业股份有限公司(以下简称:桂林集琦)于2006年12月13日发布股票继续停牌公告,称12日收到控股股东桂林集琦集团有限公司(以下简称:集琦集团)关于目前正与国海证券有限责任公司就该公司借壳桂林集琦上市有关事宜进行接洽的函,为避免公司股票价格异常波动,申请公司股票继续停牌。此信息公布后,市场反应强烈,为保证桂林集琦药业股份有限公司广大中小股东的知情权,避免做出
In view of Guilin Ji-kai Pharmaceutical Co., Ltd. (hereinafter referred to as: Guilin Ji-qi) on December 13, 2006 announcement of the suspension of shares to continue the announcement, said on the 12th received the controlling shareholder Guilin Ji-Qi Group Co., Ltd. (hereinafter referred to as: ) Concerning the letter that Guohai Securities Co., Ltd. is currently engaging in the issue of the backdoor listing of Guilin Jiqi, Guilin Securities Co., Ltd. To avoid abnormal fluctuations in the stock price of the Company, the application for suspension of the Company’s shares was suspended. After the announcement of this information, the market reacted strongly and in order to ensure the right to know the majority of minority shareholders in Guilin Jiqi Pharmaceutical Co., Ltd., to avoid making